Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

30
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

28
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Questionnaire Survey of Medical Thyroid Specialists in Korea on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients.

Endocrinology and metabolism (Seoul, Korea)·2026
Same author

Mild Thyroid Eye Disease-The Most Common yet the Least Studied Presentation of Thyroid Eye Disease.

Thyroid : official journal of the American Thyroid Association·2026
Same authorSame journal

Post-thyrotoxicosis weight gain: time to stratify and treat?

Nature reviews. Endocrinology·2026
Same author

Use of Thyroid Hormones in Patients with Hypothyroidism and Euthyroidism in the United States: American Association of Clinical Endocrinology International Collaboration with the THESIS Investigators.

AACE endocrinology and diabetes·2026
Same author

PERSPECTIVE: Prioritizing quality of life in the management of hyperthyroidism: an expert clinical perspective.

Endocrine connections·2026
Same author

Weight Gain after Treatment of Hyperthyroidism is Associated with Impairment of Quality of Life.

Thyroid : official journal of the American Thyroid Association·2025

Related Experiment Video

Updated: May 4, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

5.8K

Graves orbitopathy: a perspective.

Petros Perros1, Gerasimos E Krassas

  • 1Endocrine Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK. petros.perros@newcastle.ac.uk

Nature Reviews. Endocrinology
|May 8, 2009
PubMed
Summary
This summary is machine-generated.

Recent advances improve understanding of Graves orbitopathy (GO) pathogenesis and treatment. Intravenous steroids and orbital radiotherapy are effective, with immunotherapies like rituximab showing promise for managing this autoimmune eye condition.

More Related Videos

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.7K
Grossing of Non-neoplastic Globes, Including Fetal Eyes
05:15

Grossing of Non-neoplastic Globes, Including Fetal Eyes

Published on: May 30, 2025

751

Related Experiment Videos

Last Updated: May 4, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

5.8K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.7K
Grossing of Non-neoplastic Globes, Including Fetal Eyes
05:15

Grossing of Non-neoplastic Globes, Including Fetal Eyes

Published on: May 30, 2025

751

Area of Science:

  • Endocrinology and Immunology
  • Ophthalmology
  • Autoimmune Diseases

Background:

  • Graves orbitopathy (GO) is an autoimmune condition affecting the eyes.
  • Understanding the pathogenesis, including the roles of TSH and IGF-1 receptors, has advanced.
  • Optimal management strategies are crucial for patient outcomes.

Purpose of the Study:

  • To summarize recent advancements in understanding Graves orbitopathy pathogenesis.
  • To review current optimal treatment strategies for GO.
  • To explore emerging immunotherapies for GO management.

Main Methods:

  • Review of recent scientific literature on Graves orbitopathy.
  • Analysis of established treatment guidelines from the European Group on Graves' Orbitopathy.
  • Evaluation of evidence for steroid therapies, radiotherapy, and immunotherapies.

Main Results:

  • Intravenous steroid pulses are superior to other steroid regimens for GO treatment.
  • Orbital radiotherapy shows efficacy in a subset of patients with eye muscle dysfunction.
  • Rituximab is a promising immunotherapy agent currently under investigation for GO.

Conclusions:

  • Current understanding of GO pathogenesis has improved significantly.
  • Established treatments like IV steroids and radiotherapy offer effective management options.
  • Immunotherapies, particularly rituximab, represent a potential future direction for GO treatment.